Astellas has said it will book a $170 million ... both in early-stage clinical development – along with DMD gene therapies AT702, AT751 and AT753. The full financial impact of the delay to ...

With the safety of gene therapies thrown into the spotlight by a series of FDA clinical holds, Astellas has said that an interim readout in a phase 1/2 trial of its Pompe disease candidate AT845 ...

BOSTON & MONTREAL, June 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, ...

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

After two years of quietly shifting its medical affairs and commercial strategy units under one roof, Astellas is entering ... brought to market two oncology therapies in Padcev and Vyloy, plus ...

In June 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive intismeran autogene and ...

Could a Medicated Foam Make Gene Therapies More Accessible? May 29, 2024 — Bioengineers report that a foaming liquid worked better than a standard liquid formulation at transferring gene therapy ...